All In Biotech

Drug Trial Radar · NCT06343779

Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

A Phase 3, Randomized, Double-blind, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults With Hereditary Angioedema

Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 134 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

134

Actual

Start

Feb 26, 2024

Primary completion

Oct 17, 2025

Study completion Oct 17, 2025

Sponsor

Lead sponsor
Pharvaris Netherlands B.V.Industry
Sponsor type
Industry
First posted
Apr 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryngeal attacks, in participants ≥12 to ≤75 years of age with HAE type 1, type 2, or type 3, a proportion of whom are using long-term prophylactic medication for HAE.

Conditions

  • Hereditary Angioedema
  • Hereditary Angioedema Type I
  • Hereditary Angioedema Type II
  • Hereditary Angioedema Types I and II
  • Hereditary Angioedema Attack
  • Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
  • Hereditary Angioedema - Type 1
  • Hereditary Angioedema - Type 2
  • C1 Esterase Inhibitor [C1-INH] Deficiency
  • C1 Esterase Inhibitor Deficiency
  • C1 Esterase Inhibitor, Deficiency of
  • C1 Inhibitor Deficiency
  • Hereditary Angioedema - Type 3
  • Hereditary Angioedema Type III

Interventions

  • Deucrictibant, PlaceboDrug

    Deucrictibant Soft Capsules for Oral Use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to onset of symptom relief, defined as Patient Global Impression of Change (PGI-C) rating of at least "a little better" for 2 consecutive timepoints within 12 hours post-treatment.Time frame: Pre-treatment to 12 hours post-treatment.

Locations

76 sites in 29 countries. Site status is shown where the registry gives one.

  • Study Site

    Birmingham, Alabama

  • Study Site

    Paradise Valley, Arizona

  • Study Site

    Little Rock, Arkansas

  • Study Site

    San Diego, California

  • Study Site

    Santa Monica, California

  • Study Site

    Walnut Creek, California

  • Study Site

    Colorado Springs, Colorado

  • Study Site

    Chevy Chase, Maryland

  • Study Site

    Boston, Massachusetts

  • Study Site

    Detroit, Michigan

  • Study Site

    St Louis, Missouri

  • Study Site

    Hershey, Pennsylvania

  • Study Site

    Dallas, Texas

  • Study Site

    Buenos Aires, Argentina

  • Study Site

    Salta, Argentina

  • Study Site

    Box Hill, Australia

  • Study Site

    Campbelltown, New South Wales, Australia

  • Study Site

    Graz, Austria

  • Study Site

    Linz, Austria

  • Study Site

    Vienna, Austria

  • Study Site

    Paraná, Brazil

  • Study Site

    Ribeirão Preto, Brazil

  • Study Site

    Salvador, Brazil

  • Study Site

    Santo André, Brazil

  • Study Site

    São Paulo, Brazil

  • Study Site

    Sofia, Bulgaria

  • Study Site

    Sofia, Bulgaria

  • Study Site

    Edmonton, Alberta, Canada

  • Study Site

    Bogotá, Colombia

  • Study Site

    Bogotá, Colombia

  • Study Site

    Bogotá, Colombia

  • Study Site

    Medellín, Colombia

  • Study Site

    Brno, Czechia

  • Study Site

    Lille, France

  • Study Site

    Paris, France

  • Study Site

    Berlin, Germany

  • Study Site

    Frankfurt am Main, Germany

  • Study Site

    Frankfurt am Main, Germany

  • Study Site

    Lübeck, Germany

  • Study Site

    Hong Kong, Hong Kong

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.